张玉美,韩雅玲,荆全民,王效增,李毅,张磊,霍勇,张岩

• 1:沈阳军区总医院心内科
• 2:北京大学第一医院心内科

摘要(Abstract)：

目的探讨冠心病患者冠状动脉病变范围及狭窄程度与血脂的关系。方法 9847例疑诊冠心病并行诊断性冠状动脉造影的住院患者中,确诊冠心病6419例(65.2%),排除3428例(34.8%),以冠状动脉造影阳性(主要血管直径狭窄≥50%)作为诊断冠心病的标准。冠状动脉造影病变程度采用Gensini积分评价。术前进行甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)检查,对比分析冠心病组冠状动脉狭窄程度及范围与血脂的关系。结果对6419例冠心病患者进行统计学分析显示TC、LDL-C随着冠状动脉病变支数及病变程度(冠状动脉病变Gensini积分)的增加而升高,并与之成明显的负相关(P<0.001);而高密度脂蛋白则随着病变支数和病变程度(冠状动脉病变Gensini积分)的增加而降低,呈明显的负相关(P<0.001),进一步多元线性回归分析显示HDL-C(β=-0.075,OR值-5.580,95%CI:-7.541～-3.618,P<0.001)与冠状动脉病变程度成独立正相关,低密度脂蛋白(β=0.067,OR值2.712,95%CI:0.943～4.481,P=0.003)与冠状动脉病变程度成独立正相关,而与TG(β=0.002,OR值0.067,95%CI:-0.689～0.822,P=0.863)、TC(β=0.034,OR值1.080,95%CI:-0.392～2.553,P=0.150)无独立相关性。结论 TG、TC、LDL-C可以作为冠心病的危险因素,而HDL-C与冠状动脉病变程度成独立负相关,LDL-C与冠状动脉病变程度成独立正相关。虽然TG和TC在本研究中未体现出与冠状动脉病变程度存在独立相关性,但因本研究为横断面研究,研究结果存在一定的局限性,应结合临床具体分析。所以积极控制血脂对防止冠心病有积极意义。

关键词(KeyWords)： 冠状动脉疾病;高脂血症;冠状血管造影术

Abstract:

Keywords:

基金项目(Foundation): “十一五”国家科技支撑计划项目(2006BAI01A02)

作者(Author): 张玉美,韩雅玲,荆全民,王效增,李毅,张磊,霍勇,张岩

参考文献(References)：

• [1]Curb JD,AbbottRD,Rodrigues BL,et al.A prospective study of HDL-C and cholestergl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly.Lipid Res,2004,45:948-953.
• [2]Sasaki KJ.Treatment of hyerlipidemia from Japanese evidence.Atheroscler Thromb,2006,13:267-280.
• [3]Sharrett AR,Ballantyne CM,Coady SA,et al.Coronary heart disease Prediction from lipoprotein cholesterol levels,triglycerides,lipoprotein(a),apolipoproteins A-I and B,and HDL density Subfractions:The Atherosclerosis Risk in Communities(ARIC)Study.Circulation,2001,104:1108-1113.
• [4]Teramoto T,Sasaki J,Ueshima H,et al.Committee for E,Clinical Management of A:Goals of dyslipidemia management.Atheroscler Thromb,2007,14:209-212.
• [5]Gensini GG.A more meaningful scoring system for determining the severity of coronary heart disease.Am J Cardiol,1983,51:606.
• [6]中华心血管杂志编辑委员会.血脂异常防治对策专题组.血脂异常防治建议.中华心血管杂志,1997,25:169-170.
• [7]Chobanian AV,Bakris GL,Black HR,et al.Seventh report of the joint national committee on prevention,detection,evaluation,and treatment of high blood pressure.Hypertension,2003,42:1206-1252.
• [8]The LIPID Study Group(Long-term Intervention with Pravastain in Ischaemic Disease).Long-term efectiveness and safety of pravastatin in9014patients with coronary heart disease and verage cholesterol concentrations:the lIPID trial follow-up.Lancet,2002,359:1379-1387.
• [9]吴兆苏,赵崇华,赵冬,等.中国多省市心血管病趋势及决定因素的人群检测(中国MONICA方案)Ⅲ.危险因素水平与心血管病的联系.中华心血管病杂志,1998,26:85-88.
• [10]Gotto AM.Statin therapy:Where are we?Where do we go next.Am J Cardiol,2001,87Supp1:13-18.
• [11]Summary of the second report of the National Cholesterol Education Program(NCEP)expert panel on detection Evaluation and treatment of high blood cholesterol:In adults(Adult Treatment PaneⅡ).JAMA,1993,269:3015-3023.
• [12]陈在嘉,高润霖,主编.冠心病.北京:人民卫生出版社,2002:131-132.
• [13]Gordon T,Castelli WP,Hjortland MC,et al.High density lipoprotein as a protective factor against coronary heart disease.The Framingham Study.Am Med,1977,4:707-714.
• [14]Gordon DJ,Probstfield JL,Garrison RJ,et al.High-density lipoprotein cholesterol and cardiovascular disease Four propective American studies.Circulation,1989,79:8-15.
• [15]Ose L,Shah A,Davies MJ,et al.Consistency of lipid-altering effects of ezctimibe simvastatin across gender,race,age,baseline low desity lipoprotein cholesterol levels,and coronary heart disease status;results of a pooled retmspective analysis.Curr Med Res Opin,2006,22:823-835.